Australian biopharma company developing therapeutic cannabinoid products and psychedelic medicines Incannex Healthcare (NASDAQ: IXHL) announced that its Phase 2 clinical trial assessing proprietary psilocybin-assisted psychotherapy for Generalized Anxiety Disorder (GAD) treatment achieved its interim milestone and the analysis of the data has begun.

The study, led in collaboration with the head of the clinical psychedelic lab at Monash University and a member of the Incannex scientific advisory board Dr. Paul Liknaitzky, is set to assess safety and efficacy as well as …

Full story available on Benzinga.com